In a phase III clinical trial presented at the annual ASCO conference, the selective BRAF inhibitor dabrafenib was shown to improve progression-free survival compared with dacarbazine in patients with metastatic melanoma (median progression-free survival 5.1 months versus 2.7 months). In the same session, data from a phase II trial were presented that showed that, in assessed patients with intracranial metastases and a V600E/K substitution, dabrafenib had activity in treating intracranial and extracranial metastases.
ORIGINAL RESEARCH PAPERS
Hauschild, A. et al. Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma. J. Clin. Oncol. 30 (Suppl.), LBA8500^ (2012)
Kirkwood, J. M. et al. BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets). J. Clin. Oncol. 30 (Suppl.), a8501 (2012)
Rights and permissions
About this article
Cite this article
BRAF kinase inhibitor shows efficacy in brain metastases. Nat Rev Clin Oncol 9, 428 (2012). https://doi.org/10.1038/nrclinonc.2012.109
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2012.109
